ANXA2
ATC code L01
AUNP12
Abagovomab
Abemaciclib
Abituzumab
Abrilumab
Acalabrutinib
Adagrasib
Adalimumab
Adecatumumab
Adipotide
Afatinib
Afelimomab
Aflibercept
Alectinib
Alemtuzumab
Alpelisib
Amatuximab
American Society of Health-System Pharmacists
Amivantamab
Anaplastic lymphoma kinase
Anatomical Therapeutic Chemical Classification System
Anatumomab mafenatox
Andecaliximab
Anifrolumab
Anrukinzumab
Antigen
Antineoplastic
Apolizumab
Asciminib
Ascrinvacumab
Aselizumab
Atezolizumab
Atezolizumab/hyaluronidase
Atorolimumab
Aumolertinib
Avapritinib
Avdoralimab
Avelumab
Axatilimab
Axitinib
BMS-202
BMS-986189
BRAF (gene)
Balstilimab
Baricitinib
Basiliximab
Bavituximab
Bcr-abl fusion protein
Bectumomab
Belantamab mafodotin
Belimumab
Benralizumab
Bermekimab
Bertilimumab
Besilesomab
Bevacizumab
Bimekizumab
Binimetinib
Biological half-life
Bivatuzumab mertansine
Bleselumab
Blinatumomab
Bosutinib
Botensilimab
Brazikumab
Breakthrough therapy
Brentuximab vedotin
Briakinumab
Brigatinib
Brodalumab
Brontictuzumab
Bruton's tyrosine kinase
C-Met
CA-170
CAS Registry Number
CD117
CD135
CD20
CD30
CD33
CD3 (immunology)
CD52
CDK inhibitor
Cabozantinib
Camidanlumab tesirine
Camrelizumab
Canakinumab
Cancer immunotherapy
Cantuzumab mertansine
Cantuzumab ravtansine
Capmatinib
Carlumab
Carotuximab
Catumaxomab
Cedelizumab
Cediranib
Cemiplimab (data page)
Ceritinib
Certolizumab pegol
Cervical cancer
Cetuximab
Checkpoint inhibitor
ChemSpider
Chemical formula
Chimeric antibody
Cirmtuzumab
Citatuzumab bogatox
Cixutumumab
Clazakizumab
Clenoliximab
Clinical trial
Cobimetinib
Cofetuzumab pelidotin
Committee for Medicinal Products for Human Use
Conatumumab
Copanlisib
Cosibelimab
Crizanlizumab
Crizotinib
Dabrafenib
Dacetuzumab
Daclizumab
Dacomitinib
DailyMed
Dalotuzumab
Dalpiciclib
Daratumumab
Dasatinib
Demcizumab
Denileukin diftitox
Denintuzumab mafodotin
Depatuxizumab mafodotin
Detumomab
Dinutuximab
Dinutuximab beta
Doi (identifier)
Dostarlimab
Drozitumab
DrugBank
Drug nomenclature
Drugs.com
Duligotumab
Dupilumab
Durvalumab
Dusigitumab
Duvelisib
Duvortuxizumab
EML4
Ecromeximab
Eculizumab
Edrecolomab
Efalizumab
Eldelumab
Elotuzumab
Elranatamab
Elsilimomab
Emactuzumab
Emapalumab
Emibetuzumab
Encorafenib
Enfortumab vedotin
Enoblituzumab
Enoticumab
Ensituximab
Entrectinib
EpCAM
Epcoritamab
Epidermal growth factor receptor
Epratuzumab
ErbB
Erdafitinib
Erlizumab
Erlotinib
Ertumaxomab
Etaracizumab
Etrolizumab
European Medicines Agency
Everolimus
Exotoxin
Faralimomab
Farletuzumab
Fedratinib
Fezakinumab
Fibroblast growth factor receptor
Ficlatuzumab
Figitumumab
Filgotinib
Flanvotumab
Fletikumab
Flotetuzumab
Fontolizumab
Food and Drug Administration
Fresolimumab
Frexalimab
Fruquintinib
Fusion protein
Futibatinib
Futuximab
Galiximab
Ganitumab
Gavilimomab
Gefitinib
Gemtuzumab ozogamicin
Gevokizumab
Gilteritinib
Girentuximab
Glasdegib
Glembatumumab vedotin
Glofitamab
Golimumab
Gomiliximab
Guselkumab
HER2/neu
Health Canada
Hedgehog signaling pathway
Hepatitis
Human
Humanized antibody
Hyperthyroidism
Hypothyroidism
Ianalumab
Ibalizumab
Ibritumomab tiuxetan
Ibrutinib
Icotinib
Icrucumab
Idelalisib
Imatinib
Imgatuzumab
Immune system
Immunosuppression
Inavolisib
Indatuximab ravtansine
Indium (111In) altumomab pentetate
Indium (111In) capromab pendetide
Indium (111In) igovomab
Indium (111In) satumomab pendetide
Inebilizumab
Infigratinib
Infliximab
Inolimomab
Inotuzumab ozogamicin
Interleukin
Interleukin 2
Intetumumab
Intravenous
Iodine (131 I) derlotuximab biotin
Ipilimumab
Iratumumab
Isatuximab
Istiratumab
Itolizumab
Ixekizumab
Janus kinase
KEGG
KN035
KRAS
Keliximab
Labetuzumab
Lampalizumab
Lanadelumab
Lapatinib
Larotrectinib
Lazertinib
Lebrikizumab
Lemalesomab
Lenvatinib
Lenzilumab
Lerdelimumab
Lesion
Lestaurtinib
Letolizumab
Leukemia
Lexatumumab
Lifastuzumab vedotin
Ligelizumab
Lilotomab
Lintuzumab
Lirentelimab
Lirilumab
List of withdrawn drugs
Lokivetmab
Loncastuximab tesirine
Lorlatinib
Lorvotuzumab mertansine
Lucatumumab
Lulizumab pegol
Lumiliximab
Lumretuzumab
Lung cancer
Lymphatic system
Lymphoma
MEN1
MTOR inhibitor
Mapatumumab
Margetuximab
Masitinib
Maslimomab
Matuzumab
Mavrilimumab
MedlinePlus
Mepolizumab
Metelimumab
Midostaurin
Milatuzumab
Minretumomab
Mirikizumab
Mirvetuximab soravtansine
Mitogen-activated protein kinase kinase
Mitumomab
Mobocertinib
Mogamulizumab
Molar mass
Momelotinib
Monoclonal antibodies
Monoclonal antibody
Monoclonal antibody therapy
Morolimumab
Mosunetuzumab
Moxetumomab pasudotox
Myeloid
Myeloma
Nacolomab tafenatox
Namilumab
Naptumomab estafenatox
Narnatumab
Natalizumab
Naxitamab
Necitumumab
Neoplasm
Neratinib
Nerelimomab
Nesvacumab
Nilotinib
Nimotuzumab
Nintedanib
Nivolumab
Nivolumab/relatlimab
Non-receptor tyrosine kinase
Obinutuzumab
Ocaratuzumab
Ocrelizumab
Ocrelizumab/hyaluronidase
Odronextamab
Odulimomab
Ofatumumab
Olaratumab
Oleclumab
Olmutinib
Olokizumab
Omalizumab
Onartuzumab
Ontamalimab
Ontuxizumab
Oportuzumab monatox
Oregovomab
Orelabrutinib
Osimertinib
Otelixizumab
Otlertuzumab
Oxelumab
Ozoralizumab
PD-1
PD-1 and PD-L1 inhibitors
PMC (identifier)
PMID (identifier)
PRO 140
Pacritinib
Palbociclib
Pamrevlumab
Panitumumab
Parsaclisib
Parsatuzumab
Pascolizumab
Pateclizumab
Patritumab
Pazopanib
Pembrolizumab
Pemigatinib
Pemtumomab
Perakizumab
Pertuzumab
Pexelizumab
Pexidartinib
Pharmacokinetics
Phases of clinical research
Pi3K inhibitor
Pidilizumab
Pinatuzumab vedotin
Pirtobrutinib
Placulumab
Platelet-derived growth factor receptor
Plozalizumab
Pneumonitis
Polatuzumab vedotin
Ponatinib
Pralsetinib
Pregnancy category
Prescription drug
Priliximab
Priority review
Pritumumab
Proapoptotic
Programmed cell death protein 1
Programmed death-ligand 1
Prohibitin
Prolgolimab
Public domain
Quilizumab
Quizartinib
RET proto-oncogene
RTK class III
Racotumomab
Radotinib
Radretumab
Ramucirumab
Ravulizumab
Receptor tyrosine kinase
Regorafenib
Regulation of therapeutic goods
Relatlimab
Repotrectinib
Reslizumab
Retifanlimab
Revumenib
Ribociclib
Ridaforolimus
Rilotumumab
Ripretinib
Risankizumab
Rituximab
Robatumumab
Rociletinib
Rontalizumab
Rosmantuzumab
Route of administration
Rovalpituzumab tesirine
Rovelizumab
Rozanolixizumab
Ruplizumab
Ruxolitinib
S2CID (identifier)
Sabatolimab
Sacituzumab govitecan
Samalizumab
Sarilumab
Satralizumab
Secukinumab
Selpercatinib
Selumetinib
Semaxanib
Seribantumab
Serplulimab
Sibrotuzumab
Sifalimumab
Siltuximab
Simtuzumab
Siplizumab
Sirolimus
Sirukumab
Skin reaction
Sofituzumab vedotin
Solitomab
Sonidegib
Sorafenib
Sotorasib
Spartalizumab
Spesolimab
Squamous cell carcinoma
Squamous cell skin cancer
Src (gene)
Standard for the Uniform Scheduling of Medicines and Poisons
Stevensâ€“Johnson syndrome
Sugemalimab
Sunitinib
Sutimlimab
TGN1412
Tabalumab
Tafasitamab
Talizumab
Talquetamab
Taplitumomab paptox
Tarextumab
Targeted cancer therapy
Tarlatamab
Tebentafusp
Technetium (99mTc) arcitumomab
Technetium (99mTc) fanolesomab
Technetium (99mTc) nofetumomab merpentan
Technetium (99mTc) pintumomab
Technetium (99mTc) sulesomab
Technetium (99mTc) votumumab
Teclistamab
Telimomab aritox
Temsirolimus
Tenatumomab
Teneliximab
Teplizumab